New U.S. Composition of Matter Patent for Aradigm Corporation (ARDM)'s Pulmaquin™ and Lipoquin™ Provides Protection Until 2031
9/18/2012 8:41:07 AM
HAYWARD, Calif.--(BUSINESS WIRE)--Aradigm Corporation (OTCBB: ARDM) ("Aradigm" or the “Company”) today announced that the United States Patent and Trademark Office has issued an important new composition of matter patent (U.S. Patent No. 8,268,347) to Aradigm for formulations of liposomal and free ciprofloxacin, including its lead compound Pulmaquin. This patent provides new coverage for Lipoquin and extends protection for Pulmaquin until February 11, 2031.
comments powered by